# Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism

> **NCT01759888** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 49 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** 18F-DTBZ

## Key facts

- **NCT ID:** NCT01759888
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2015-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01759888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01759888, "Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01759888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*